Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Abiraterone in metastatic prostate cancer without previous chemotherapy.
Abiraterone improved radiographic progression-free survival, showed a trend toward improved overall survival, and significantly delayed clinical decline and initiation of chemotherapy in patients with metastatic castration-resistant prostate cancer.
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
NCCN clinical practice guidelines in oncology: prostate cancer.
Apalutamide Treatment and Metastasis‐free Survival in Prostate Cancer
Among men with nonmetastatic castration‐resistant prostate cancer, metastasis‐free survival and time to symptomatic progression were significantly longer with apalutamide than with placebo.
Adverse effects of androgen deprivation therapy and strategies to mitigate them.
Changes in body composition during androgen deprivation therapy for prostate cancer.
- Matthew R. Smith, J. Finkelstein, P. Kantoff
- MedicineThe Journal of clinical endocrinology and…
- 1 February 2002
GnRH agonists increase weight and percentage fat body mass and decrease percentage lean body mass, fat distribution, and muscle size in men with nonmetastatic prostate cancer.
Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer.
- N. Keating, A. J. O’Malley, Matthew R. Smith
- Medicine, BiologyJournal of clinical oncology : official journal…
- 20 September 2006
GnRH agonist treatment for men with locoregional prostate cancer may be associated with an increased risk of incident diabetes and cardiovascular disease and the benefits of GnRH agonists should be weighed against these potential risks.
Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.
- Matthew R. Smith, J. Eastham, D. Gleason, D. Shasha, S. Tchekmedyian, N. Zinner
- MedicineThe Journal of urology
- 1 June 2003
Zoledronic acid increases bone mineral density in the hip and spine during androgen deprivation therapy for nonmetastatic prostate cancer and was well tolerated.
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a…